CA2693600C — Pyridazinone derivatives
Assigned to Merck Patent GmbH · Expires 2015-10-06 · 11y expired
What this patent protects
Compounds of the formula (I): (see formula I) in which R1, R2, R3, R4, R4' are each as defined in the specification are inhibitors of tyrosine kinases, especially of Met kinase, and can be used, inter alia, for treatment of tumours.
USPTO Abstract
Compounds of the formula (I): (see formula I) in which R1, R2, R3, R4, R4' are each as defined in the specification are inhibitors of tyrosine kinases, especially of Met kinase, and can be used, inter alia, for treatment of tumours.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.